Clinical Trials Browser

Phase 2 × Alzheimer Disease × 1 year × Clear all

NCT06745583 2026-06-03

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Phase 2 Recruiting

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT06362707 2026-05-04

FEAD

Phase 2 Recruiting

Alzheimer Disease, Lymphoma, Follicular, Cognitive Dysfunction

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Phase 2 Terminated

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT06723015 2025-11-18

Tau PET Outcomes With Anti-amyloid Immunotherapies

Phase 2 Enrolling by invitation

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction